ClinicalTrials.gov competitor trial landscape: how launch teams map a crowded indication

A launch team preparing a prostate cancer asset opens ClinicalTrials.gov to size the competitive field and finds 2,660 trials. Scrolling the list answers almost nothing: the raw count mixes pivotal Phase 3 reads with single-site dose-escalations, sponsor-led registration studies with academic investigator trials, and active recruiting studies with records abandoned to "Unknown" status. What the team needs is not the count but a structured read of the field — how many trials are in late-phase development, how many are actively recruiting, which sponsors are running the pivotal program, and which mechanism classes are saturated versus open. That read is the difference between launching into evidence the field has already generated and finding a positioning window the registry reveals. The map is built from six filters applied in order, and it turns a 2,660-record fire hose into a competitive landscape a launch strategy can act on.

ClinicalTrials.gov, maintained by the National Library of Medicine, is the world's largest public clinical-research registry, with roughly 589,000 studies registered. This article is a competitor-mapping workflow for that registry, written for pipeline, launch, evidence, and market-access teams who need to scope an indication before planning a development program or a payer-evidence package. It covers how to construct the search, which fields answer which strategic question, the registration and results-posting rules that shape what the data can and cannot show, and a worked competitive map of prostate cancer as the field stands. It is not a clinical recommendation. For the registry-wide statistics — sponsorship concentration, the Phase 3 results-reporting gap, and accrual as the dominant reason trials terminate — see the companion ClinicalTrials.gov by the numbers analysis; this article stays on the per-indication competitive read a launch team runs.

The legal backbone: why the registry is complete enough to map

The reason a launch team can map a field from ClinicalTrials.gov with any confidence is that registration is, for most industry drug trials, mandatory. Under Section 801 of the FDA Amendments Act of 2007 (FDAAA 801), as implemented by the 2016 Final Rule (42 CFR Part 11), "applicable clinical trials" of drugs and biologics — generally controlled trials other than Phase 1 investigations — must be registered within 21 days of enrolling the first participant, and summary results must be submitted no later than one year after the primary completion date, even for unapproved products. Noncompliance carries civil monetary penalties that escalate per day and can be applied until the record is corrected, and FDA Notices of Noncompliance surface in a dedicated FDAAA 801 Violation field on the study record. The practical consequence for a launch team is that a sponsor running a registrational trial in a crowded indication has a legal obligation to list it, which makes the registry a structurally complete view of the active competitive program — provided the team reads the fields that distinguish a real commitment from noise.

Step 1 — Define the indication boundary with the Condition field

The first and most error-prone step is constructing the condition search. ClinicalTrials.gov exposes a dedicated Condition/disease field, and industry best practice for therapeutic-area monitoring is to use it rather than free-text terms. A condition-field search for "prostate cancer" returns studies whose registered condition is prostate cancer, whereas the same words in a general-term search return every study that merely mentions prostate cancer in its eligibility text — including trials that exclude it — which inflates the count with irrelevant records. The condition field is autocomplete-backed and maps to recognized disease terms, which improves consistency across sponsors who phrase the same indication differently. For the worked example here, a condition search capturing prostate cancer returns 2,660 interventional and observational trials registered with a 2020–2026 start; the boundary the launch team sets at this step determines every downstream count.

Step 2 — Filter to interventional trials and the phases that matter

A registry map is only useful once it separates the trials that change the evidence bar from those that do not. The Study Type filter separates interventional trials from observational studies and patient registries; for competitive landscape purposes, the launch team typically restricts to interventional. The Study Phase filter then separates the developmental stages, using enumerated values Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4, and Not Applicable. For the prostate cancer field, the phase distribution of the 2,660 trials is:

The number a launch team fixes on is 165 Phase 3 trials — the registrational and late-phase competitive set. That is the crowd a new asset's evidence package will be compared against, and it is the field's measure of how high the evidence bar sits. A field with single-digit Phase 3 activity is wide open; 165 is deeply contested, and it tells the team that differentiation — by line of therapy, biomarker, combination, or endpoint — is not optional.

The raw Phase 3 count becomes a commercial estimate only after attrition is applied. Published transition-rate benchmarks — roughly 71% of Phase 1 candidates advancing to Phase 2, about 45% of Phase 2 candidates advancing to Phase 3, and on the order of 19% of drugs entering Phase 1 ultimately reaching approval — are the lens a launch team applies to the funnel. A prostate cancer field carrying 255 Phase 1, 466 Phase 2, and 165 Phase 3 trials is feeding the approval pipeline at a rate that implies sustained competitive entry for years even after the historical attrition, which is why a crowded late-phase field is read as a multi-year rather than a one-cycle problem. The attrition lens also reads failure the other way: a high terminated count among those Phase 3s trims the expected-approvals estimate back down, and pulling the "why stopped" field tells the team whether the attrition is mechanism-wide (a class problem) or asset-specific (an execution problem).

Step 3 — Read status to find the live competitive threat

Phase counts include trials completed years ago, which are no longer competitive. The Study Status field separates the live program from history, using values such as Recruiting, Active Not Recruiting, Not Yet Recruiting, Completed, Terminated, Withdrawn, Suspended, and Unknown. For prostate cancer, the status distribution is:

The actionable number is roughly 1,658 trials in a live or impending state (recruiting, active, not-yet-recruiting, enrolling by invitation), and within those the recruiting Phase 3 subset is the near-term readout wave a launch team must sequence against. A high Terminated count (126 here) is itself a signal: pulling the "why stopped" field for terminated Phase 3s surfaces the efficacy, safety, or accrual failures that map where the field has already struggled — intelligence a launch team uses to de-risk its own design.

Step 4 — Map the sponsors: who is running the pivotal program

The registry's Sponsor/Collaborator and Lead Sponsor fields, combined with the sponsor-class enumeration (Industry, NIH, Other, Network, Federal), reveal who is driving the field and how concentrated it is. In prostate cancer, the sponsor-class split is 74% academic and other (1,975 trials), 21% industry (571), and the remainder NIH, cooperative groups, and federal sponsors. Industry runs the minority of trials by count but concentrates its spend where the commercial decision sits — in Phase 3. The Phase 3 lead-sponsor set for prostate cancer is led by AstraZeneca (6), Merck (5), Novartis (5), Pfizer (4), Jiangsu Hengrui (4), and Janssen (3), with cooperative groups (NRG Oncology, Alliance, UNICANCER) contributing multi-site registrational infrastructure.

This map answers the strategic question a launch team cares about: against whom does the new asset actually compete? The Phase 3 leader list is the competitive set for evidence positioning; the broader lead-sponsor concentration tells the team whether the field is oligopolistic (a few sponsors controlling pivotal activity, easier to track and partner against) or fragmented (many sponsors, harder to displace but less coordinated). For prostate cancer, a handful of large sponsors dominate late phase, which means a new entrant's positioning must contend with named, well-resourced registrational programs rather than a diffuse long tail.

Step 5 — Map the mechanism classes: where the saturation and white space sit

The most strategically load-bearing step is classifying the trials by mechanism, using the Intervention/treatment field. Because the registry records interventions as free text, a launch team maps mechanism classes by keyword grouping over the intervention field. For prostate cancer, the mechanism-class counts in the 2,660-trial field are:

Aggregating the androgen-receptor pathway inhibitors (abiraterone, enzalutamide, darolutamide, apalutamide) yields 366 trials — the field's saturated backbone, where a new mechanism-class asset faces entrenched standards of care and combination-partner incumbency. The PSMA radioligand cluster (108) is the fast-growing wave, built on lutetium-177 vipivotide tetraxetan (Pluvicto) and now expanding into actinium-225 conjugates and earlier disease settings, with trials like VISION, TheraP, and PSMAfore defining the evidence. PARP inhibitors (51) and PD-(L)1 (60) represent the biomarker-selected and immunotherapy combination fronts, where trial activity is dense but the registrational wins remain population-specific. The white space — AR degraders and PSMA-directed T-cell engagers — shows single-digit counts, marking the emerging classes a differentiated launch could enter ahead of the crowd. This mechanism map is what converts the registry into a positioning decision: enter where the count is high and compete on execution, or enter where the count is low and compete on mechanism.

Step 6 — Read the results-posting and FDAAA 801 discipline

A field's competitive map is only as trustworthy as its sponsors' disclosure discipline. The registry exposes a Results Submitted filter and an FDAAA 801 Violations filter that a launch team uses to assess whether the field's evidence is actually public. Applicable clinical trials are required to post results within a year of primary completion; a field in which many completed Phase 3s carry no posted results is a field with hidden evidence, which both raises the uncertainty a launch team faces and, conversely, may signal competitor readouts that have not yet been disclosed. The FDAAA 801 Violations field surfaces formal Notices of Noncompliance, which are rare but indicate sponsors that have failed registration or results obligations. For evidence planning, a launch team treats the results-posting rate as a data-quality overlay: a crowded field with strong posting discipline yields a reliable evidence map; a crowded field with poor posting discipline requires deeper literature and congress-proceeding surveillance to fill the gaps the registry leaves.

The mapping workflow, before any evidence-plan decision

1. Search the Condition field, not free text. Use the structured condition field to bound the indication; avoid general-term searches that inflate counts with exclusion-only records.
2. Filter to interventional and the relevant phases. Fix on Phase 3 as the evidence bar; read Phase 2 for mechanism read-through and Phase 4 for label-expansion activity.
3. Read status for the live program. Restrict the competitive threat to recruiting and active-not-recruiting; read terminated Phase 3s for where the field has failed.
4. Map lead sponsors and sponsor class. Identify the Phase 3 competitive set and whether the field is concentrated or fragmented; these are the named programs a launch positions against.
5. Classify by mechanism. Aggregate intervention keywords into mechanism classes to find saturation (high counts) and white space (low counts); this is the positioning decision.
6. Overlay results posting and FDAAA 801. Treat the posting rate as a data-quality overlay and flag hidden evidence that requires secondary surveillance.
7. Convert the map into decisions. Use the Phase 3 count to set the evidence bar, the mechanism map to choose positioning, the sponsor concentration to identify partner or acquisition targets, and the status wave to time launch sequencing against near-term readouts.

What pipeline and launch teams should take from the map

For pipeline and launch teams, the value of the ClinicalTrials.gov map is not the headline count but the structured read behind it: the 165 Phase 3 trials set the evidence bar for entering prostate cancer, the mechanism-class map shows a saturated androgen-receptor backbone (366 ARPI trials) and a fast-growing PSMA radioligand cluster (108) against near-white-space emerging classes, and the sponsor concentration identifies the named registrational programs — AstraZeneca, Merck, Novartis, Pfizer, Janssen — a differentiated asset must position against. For evidence and market-access teams, the same map frames the payer-evidence question: a launch into a 165-Phase-3 field must justify why one more trial changes the formulary calculus, and the mechanism map shows whether the asset enters a crowded, well-evidenced class (where comparative data is the price of entry) or an emerging class (where earlier, smaller evidence packages may suffice). And for any team running this mapping exercise, the discipline is to repeat it on a cadence: the registry's recruiting and not-yet-recruiting counts change monthly, the terminated Phase 3 set accumulates failure intelligence, and the mechanism map shifts as emerging classes move from single digits into contention. A map built once goes stale; a map rebuilt quarterly is a competitive-intelligence asset. The cadence is operationalized with saved searches and RSS feeds on the registry's status and phase fields, and the map is triangulated against patent and exclusivity data (Orange Book for small molecules, Purple Book for biologics) so that a registry cluster of Phase 1 registrations from one sponsor — a near-term read on commitment — is confirmed or discounted by whether that sponsor has also built a protecting patent estate around the mechanism. The registry shows the clinical commitment; the patent and exclusivity record shows the commercial intent; together they are a higher-confidence pipeline map than either source alone.

This article is for informational purposes only and does not constitute clinical advice, investment advice, or a recommendation to enroll in, design, or terminate any trial. ClinicalTrials.gov records change continuously; always verify current records and study statuses on clinicaltrials.gov before relying on a specific count or status in a planning document.

Last updated: June 13, 2026.

Sources

• ClinicalTrials. "ClinicalTrials.gov" (advanced search: Condition/disease, Study Status, Study Phase, Study Type, Sponsor, Results Submitted, FDAAA 801 Violations filters; Studies by Topic). clinicaltrials.gov
• ClinicalTrials. "How to Search for Studies on ClinicalTrials.gov" (condition-field versus general-term searching; refining and modifying searches). clinicaltrials.gov
• ClinicalTrials. "Clinical Trial Reporting Requirements" (FDAAA 801; Final Rule 42 CFR Part 11; results due within 1 year of primary completion date; FDAAA 801 Violation and Notice of Noncompliance). clinicaltrials.gov
• National Institutes of Health. "Final Rule for Clinical Trials Registration and Results Information Submission (42 CFR Part 11)" (applicable clinical trials; registration within 21 days of first enrollment; effective January 18, 2017; compliance April 18, 2017). clinicaltrials.gov
• Actulligence. "How to Use the ClinicalTrials.gov Website for Monitoring" (using the condition field to avoid noise; interpreting study status, phase, sponsor, and location for competitive monitoring; RSS feeds and saved searches). actulligence.com
• IntuitionLabs. "Find Clinical Drug Pipelines: A Complete Guide to Resources" (transition-rate benchmarks: ~71% Phase 1→2, ~45% Phase 2→3, ~19% Phase 1→approval; ClinicalTrials.gov as a primary pipeline source). intuitionlabs.ai
• DrugPatentWatch. "Track Any Drug Pipeline Through Patent Filings" (integrating patent, ClinicalTrials.gov, and regulatory data into a pipeline map; confirming a registry cluster against the patent estate). drugpatentwatch.com
• Sartor, O., et al. "Emerging Therapeutic Strategies in Prostate Cancer: PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade" (VISION, TheraP, and PSMAfore trials; PSMA PET as eligibility biomarker; evolution of lutetium-177 vipivotide tetraxetan). PMC
• Binaytara Cancer Research Institute. "Prostate Cancer in 2026: Personalizing ADT Duration, PARP Inhibitors Move Earlier, and a Bispecific That May Finally Crack Immunotherapy" (ARPIs, PARP inhibitors, lutetium-PSMA, radium-223; emerging AR degraders, CYP11 inhibitors, T-cell engagers, and ADCs in mCRPC). binaytara.org
• ClinicalTrials. "News and Updates" (Studies by Topic feature added March 2026; Search Details and release notes). clinicaltrials.gov